Loading...
Found 686 results for in-health
A listing of in-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Biomarkers for Noninvasive respiratory support in Immunocompromised Children (BioNIC)
C
Courtney Rowan, MD
What is the purpose of this study?The goal of this study is to identify and validate response to therapy biomarkers for NIV respiratory support in children with ICCs. The central hypothesis is that response-to-therapy biomarkers can identify those most likely to benefit from intervention with NIV. The rationale is that …
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program toEvaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to SeverelyActive Crohn's Disease
M
Monika Fischer, MD
What is the purpose of this study?The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study …
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance with Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress reaction Interventions with TNX-102 SL - OASIS)
P
Paul Musey, MD
This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled …
A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
M
Monika Fischer, MD
The purpose of this study is to assess the efficacy and safety of RO7790121 (formerly PF-06480605 and RVT-3101) in patients with moderately to severely active Crohn's disease (CD). RO7790121 is a fully human neutralizing immunoglobulin G monoclonal antibody (mAb) against tumor necrosis factor-like ligand 1A (TL1A). TL1A plays a central …
Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
S
Sandeep Batra, MD
This clinical trial tests the impact of a culturally-tailored home-based physical activity program on physical fitness in Hispanic or Latino/Latina adolescent and young adult (AYA) childhood cancer survivors. After treatment for cancer, some AYA survivors experience long-term effects from the cancer and its treatment including weight gain, fatigue and decreased …
A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
M
Marian Pfefferkorn
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).THIS STUDY IS ENROLLING BY INVITATION ONLY - This study is only enrolling individuals who have …
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
M
Myda Khalid
The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.THIS STUDY IS ENROLLING BY INVITATION ONLY
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (Synergy-Outcomes)
R
Raj Vuppalanchi, MD
This multicenter, randomized, parallel-arm, double-blind, placebo-controlled Phase 3 umbrella- type master protocol aims to create a framework for simultaneously evaluating the safety and efficacy of multiple pharmacologic agents (interventions) for the treatment of high-risk metabolic dysfunction-associated steatotic liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study team will …
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with Hfe-Related Hereditary Hemochromatosis
E
Eric Orman
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in …
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (Mash) (Zenith-1)
R
Raj Vuppalanchi, MD
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.THIS STUDY IS ENROLLING BY INVITATION ONLY
Please choose between Voice or SMS based delivery of verification code
or